A proof-of-concept study to evaluate treatments’ efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative early breast cancer population. (The MiRaDor study)
Phase: Phase II clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Oncologia Medica Senologica
Drug: Giredestrant, Inavolisib, Abemaciclib
Pathologies: Breast cancer
ClinicalTrials.gov: Read the details about clinical trials
This is a multicenter, open-label, Phase II clinical trial. The trial consists of two phases: 1) Surveillance phase: After signing the informed consent form, patients enter a surveillance phase to assess the incidence of ctDNA detection in patients with HR-positive/HER2-negative breast cancer. Blood samples will be collected, and ctDNA will be analyzed at various time points. If ctDNA is detected, patients will be screened for eligibility to enter the treatment phase of the study. 2) Treatment phase: Depending on the presence of a PIK3CA mutation confirmed centrally via tissue samples collected during the surveillance phase, patients will be randomized to different arms, which will be opened sequentially. ARM A: treatment with endocrine therapy (after the first three months, at the physician’s discretion, the patient may begin one of the treatments in ARMs B, C, and/or D) ARM B: Giredestrant monotherapy ARM C: Giredestrant + Abemaciclib ARM D: Giredestrant + Inavolisib
Last update: 14/07/2026